Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
9.02
-0.38 (-4.04%)
At close: Jul 18, 2025, 4:00 PM
9.07
+0.05 (0.55%)
After-hours: Jul 18, 2025, 7:50 PM EDT

Company Description

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.

It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Dyne Therapeutics, Inc.
Dyne Therapeutics logo
CountryUnited States
Founded1984
IPO DateSep 17, 2020
IndustryBiotechnology
SectorHealthcare
Employees191
CEOJohn Cox

Contact Details

Address:
1560 Trapelo Road
Waltham, Massachusetts 02451
United States
Phone781 786 8230
Websitedyne-tx.com

Stock Details

Ticker SymbolDYN
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$19.00
CIK Code0001379895
CUSIP Number26818M108
ISIN NumberUS26818M1080
Employer ID20-5653152
SIC Code4911

Key Executives

NamePosition
John G. Cox M.B.A.Chief Executive Officer, President and Director
Dr. Oxana Beskrovnaya Ph.D.Chief Innovation Officer
Johanna Friedl-NadererChief Commercial Officer
Dr. Douglas Kerr M.B.A., M.D., Ph.D.Chief Medical Officer
Erick J. Lucera C.F.A., C.P.A.Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer and Treasurer
Dr. Rajesh Manchanda Ph.D.Chief Technical Officer
James P. Bilotta M.B.A.Chief Digital and Information Officer
Dr. Ranjan Batra Ph.D.Chief Scientific Officer
Daniel WilsonSenior Vice President and Head of Legal
Lucia CelonaChief Human Resource Officer

Latest SEC Filings

DateTypeTitle
Feb 14, 2019SC 13G/A[Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2019SC 13G/A[Amend] Statement of acquisition of beneficial ownership by individuals
May 8, 2018SC 13G/A[Amend] Statement of acquisition of beneficial ownership by individuals
Apr 27, 201815-12BSecurities registration termination
Apr 27, 201810-K/A[Amend] Annual report
Apr 9, 20188-KCurrent Report
Apr 9, 2018S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Apr 9, 2018S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Apr 9, 2018POSASRFiling
Apr 9, 201825-NSEFiling